Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic

Torsten Schröder1, David Kucharczyk2, Florian Bär2

  • 1University of Lübeck, Department of Medicine I, Ratzeburger Allee 160, D-23538 Lübeck, Germany; University of Lübeck, Institute for Systemic Inflammation Research, Ratzeburger Allee 160, D-23538 Lübeck, Germany.

Molecular Metabolism
|April 13, 2016
PubMed
Abstract

Keywords:
ALT, alanine aminotransferaseAMP, adenosine monophosphateAMPK, AMP-activated proteinkinaseATP, adenosine triphosphateATP8, ATP synthase protein 8Arg, arginineAsp, aspartic acidB6-mtB6, C57BL/6B6-mtFVB, C57BL/6-mtFVB/NC0, free dl-carnitineC16, hexadecanoyl-l-carntineC18, octadecanoyl-l-carnitineCD, control dietCD3, cluster of differentiation receptor 3CPT I, carnitine-palmitoyltransferase ICYP51A1, cytochrome P450, family 51, subfamily A, polypeptide 1GAPDH, glyceraldehyde 3-phosphate dehydrogenaseGr1, granulocyte differentiation antigen 1H&E, hematoxylin–eosin stainingH2O2, hydrogen peroxideHsd17b7, 17-beta-hydroxysteroid dehydrogenase type 7IDI1, isopentenyl-diphosphate delta isomerase 1IL, interleukinIPA, ingenuity pathway analysisKEGG, Kyoto Encyclopedia of Genes and GenomesLipid metabolismLy6G, lymphocyte antigen 6 complex, locus GMCDD, methionine and choline deficient dietMSMO1, methylsterol monooxygenase 1Met, methionineMitochondrial dysfunctionMitochondrial gene polymorphismNAFL, non-alcoholic liver steatosisNAFLDNAFLD, non-alcoholic fatty liver diseaseNAS, NAFLD activity scoreNASH, non-alcoholic steatohepatitisND3, NADH dehydrogenase subunit 3OCR, oxygen consumption rateOXPHOS, oxidative phosphorylation systemPBS, phosphate buffered salineROS, reactive oxygen speciesSNPs, single nucleotide polymorphismsSOD2, superoxide dismutase 2STRING, Search Tool for the Retrieval of Interacting Genes/ProteinsSteatohepatitisTNFαTNFα, tumor necrosis factor alphaTyr, tyrosineWD, western-style dietmt, mitochondrialpAMPK, phosphorylated AMP-activated proteinkinase

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
104
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
58
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
117
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75